Lidoderm (Lidocaine) Patent Expiration, LOE Window & CMS Spending

Lidoderm (Lidocaine) by Teikoku Usa: Off-Patent Genericized (AB Competition), 8 AB generics, $1.2M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTeikoku Usa
FDA Application & PathwayN020612 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$1.2M
2024 Medicare Part D Spend$642K
2024 Medicaid Spend$603K
Reported Wholesale Price Change (CA SB 17)1 WAC filings (max 32.7% 2-yr change)